NovoCure (NVCR) reported $161.27 million in income for the quarter ended December 2024, representing a year-over-year improve of 20.6%. EPS of -$0.61 for a similar interval compares to -$0.45 a 12 months in the past.
The reported income represents a shock of -0.02% over the Zacks Consensus Estimate of $161.3 million. With the consensus EPS estimate being -$0.34, the EPS shock was -79.41%.
Whereas traders scrutinize income and earnings adjustments year-over-year and the way they examine with Wall Road expectations to find out their subsequent transfer, some key metrics all the time supply a extra correct image of an organization’s monetary well being.
As these metrics affect top- and bottom-line efficiency, evaluating them to the year-ago numbers and what analysts estimated helps traders challenge a inventory’s worth efficiency extra precisely.
Right here is how NovoCure carried out within the simply reported quarter by way of the metrics most generally monitored and projected by Wall Road analysts:
- Internet revenues- United States: $107.20 million versus $99.85 million estimated by two analysts on common.
- Internet revenues- Worldwide markets – Whole: $52.09 million versus $53.62 million estimated by two analysts on common.
- Internet revenues- Better China: $1.98 million versus $3.45 million estimated by two analysts on common.
- Internet revenues- Japan: $8.51 million in comparison with the $8.45 million common estimate primarily based on two analysts.
View all Key Company Metrics for NovoCure here>>>
Shares of NovoCure have returned -14% over the previous month versus the Zacks S&P 500 composite’s -2.2% change. The inventory at the moment has a Zacks Rank #4 (Promote), indicating that it may underperform the broader market within the close to time period.
5 Shares Set to Double
Every was handpicked by a Zacks professional because the #1 favourite inventory to realize +100% or extra in 2024. Whereas not all picks will be winners, earlier suggestions have soared +143.0%, +175.9%, +498.3% and +673.0%.
Many of the shares on this report are flying beneath Wall Road radar, which offers an awesome alternative to get in on the bottom ground.
Today, See These 5 Potential Home Runs >>
NovoCure Limited (NVCR) : Free Stock Analysis Report
This article originally published on Zacks Investment Research (zacks.com).
The views and opinions expressed herein are the views and opinions of the writer and don’t essentially replicate these of Nasdaq, Inc.
